Patents
Literature
9 results about "TNF inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections (especially reactivation of latent tuberculosis), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.
TNF inhibitor combination therapies
PCT designated stage expiredWO2024252010A1Antibody mimetics/scaffoldsAntipyreticInterstitial lung diseaseDisease
The invention provides combination therapies comprising TNF inhibitor compounds and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders such as RA, IBD, idiopathic pulmonary fibrosis, interstitial lung disease, and MS.
Owner:ISTESSO 2 LTD
Treatment of inflammatory disorders
Methods and apparatuses for treating inflammatory diseases by neurostimulation in patients who have failed to adequately respond or have become intolerant to a drug therapy (such as a TNF inhibitor and / or a JAK inhibitor).
Owner:SETPOINT MEDICAL CORP
Methods and compositions for treating cancer
ActiveUS12648948B2Peptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsPharmacy medicineDepressant
Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor
ActiveUS12558354B2Organic active ingredientsOrganic chemistryImmunologic disordersAutoimmune condition
A small molecule TNF-α inhibitor is disclosed. The compound has an activity of inhibiting the formation of a TNF-α homotrimer by specifically binding to the binding cavity of a TNF-α homodimer. A composition containing the compound as well as uses of the compound and the composition in preventing or treating autoimmune diseases and / or inflammatory diseases are disclosed. Extracellular inactivation of TNF-α through protein-protein interface destruction is the most innovative and effective method for alleviating chronic systemic inflammatory states, and TIM series compounds, which have better efficacy and lower toxicity than those of existing TNF inhibitors and have oral bioavailability, can be effectively used as leading anti-inflammatory molecules.
Owner:AJOU UNIV IND ACADEMIC COOP FOUND +1
TNF inhibitor combination therapy
The present invention provides a combination therapy comprising a TNF inhibitor compound and a mitochondrial complex I modulator (MCIM) compound that is useful in the medical field of inflammatory and progressive disorders such as RA, IBD, idiopathic pulmonary fibrosis, interstitial lung disease, and MS.
Owner:イステッソ 2 リミテッド
In vitro method for predicting the response of patients suffering from rheumatoid arthritis to a treatment with tumor necrosis factor (TNF) inhibitors
PCT designated stageWO2025196275A1Microbiological testing/measurementBiologic markerRheumatoid arthritis
The present invention refers to a method for the identification of biomarkers or biomarker signatures for predicting the response of patients suffering from rheumatoid arthritis to a treatment with tumor necrosis factor (TNF) inhibitors, or for classifying patients suffering from rheumatoid arthritis into responder or non-responder patients to a treatment with TNF inhibitors, or for monitoring patients suffering from rheumatoid arthritis to assess whether they are responding to a treatment with TNF inhibitors, or for deciding or recommending whether to treat patients suffering from rheumatoid arthritis with TNF inhibitors.
Owner:FUNDACION INST DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS)
Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
InactiveEP4410832A3Improve drug bioavailabilityImprove efficacyPeptide/protein ingredientsAntipyreticDiseaseGastrointestinal disorder
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TNF inhibitor.
Owner:BT BIDCO INC
Treatment of inflammatory disorders
Methods and apparatuses for treating inflammatory diseases by neurostimulation in patients who have failed to adequately respond or have become intolerant to a drug therapy (such as a TNF inhibitor and / or a JAK inhibitor).
Owner:SETPOINT MEDICAL CORP
Application of h018JAK as active ingredient in preparation of medicine for treating myelofibrosis
InactiveCN119424445AImprove health-related quality of lifesafeOrganic active ingredientsSkeletal disorderBone marrow fibrosisOral treatment
The invention belongs to the technical field of biological medicines, and particularly relates to application of h018JAK as an active component in preparation of a medicine for treating myelofibrosis. The h018JAK is used as an inhibitor to specifically inhibit a JAK-STAT signal channel and block the cascade amplification effect mediated by tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1 and IL-6 cytokines, so that the symptoms of the damaged joint of the RA patient are improved. The JAK1 inhibitor provides a treatment choice for RA patients, breaks through the treatment approach of traditional rheumatism drugs and biological drugs, is still effective for patients with poor treatment response of traditional DMARD and TNF inhibitors, improves the health-related life quality of the patients, is exact in safety, and is more popular with the patients in oral treatment.
Owner:JIANGSU CAREFREE PHARM CO LTD